Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients

Journal of Heart and Lung Transplantation

Volumn 23, Issue 4, 2004, Pages 461-465

  Vrtovec, B ^a   Thomas, C D ^a   Radovancevic, R ^a   Frazier, O H ^a   Radovancevic, B ^a  

^a TEXAS HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG ANTIGENICITY; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SUPERINFECTION; SURGICAL PATIENT;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS;

EID: 1842529457     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(03)00200-6     Document Type: Article

References (21)

1. Rubin R.H. Prevention of cytomegalovirus infection in organ transplant recipients. Transplant Infect Dis. 2:2000;99-100.
2. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis. 32:2001;742-751.
3. Merigan T.C., Renlund D.G., Keay S., et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 326:1992;1182-1186.
4. Patel R., Snydman D.R., Rubin R.H., et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation. 61:1996;1279-1289.
5. Koskinen P.K., Nieminen M.S., Mattila S.P., Hayry P.J., Lautenschlager I.T. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation. 55:1993;547-551.
6. Akposso K., Rondeau E., Haymann J.P., Peraldi M.N., Marlin C., Sraer J.D. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. Transplantation. 63:1997;974-976.
7. Koetz A.C., Delbruck R., Furtwangler A., et al. Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients a prospective, double-blind, placebo-controlled study. Transplantation. 72:2001;1325-1327.
8. Singh N., Paterson D.L., Gayowski T., Wagener M.M., Marino I.R. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients a randomized, controlled trial. Transplantation. 70:2000;717-722.
9. Egan J.J., Lomax J., Barber L., et al. Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients. Transplantation. 65:1998;747-752.
10. Paniagua M.J., Crespo-Leiro M.G., De la Fuente L., et al. Prevention of cytomegalovirus disease after heart transplantation preemptive therapy with 7 days' intravenous ganciclovir. Transplant Proc. 34:2002;69-70.
11. Valantine H.A. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients evidence for a beneficial effect of hyperimmune globulin. Transplant Proc. 27:(5suppl1):1995;49-57.
12. Valantine H.A., Luikart H., Doyle R., et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation. 72:2001;1647-1652.
13. Guirado L., Herreros M.A., Munoz J.M., et al. Use of cytomegalovirus antigenemia as a marker for preemptive treatment. Transplant Proc. 34:2002;67-68.
14. Nichols W.G., Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol. 16:2000;25-40.
15. Heemann U., Wenzel R.R. CMV prophylaxis what is valid in 2002? Nephrol Dial Transplant. 17:2002;556-559.
16. Radovancevic B., Radovancevic R., Thomas C.D., et al. Preemptive antiviral therapy in cytomegalovirus negative recipients of hearts from CMV positive donors is superior to prophylaxis. J Heart Lung Transplant. 19:2000;65.
17. Avery R.K. Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients. Curr Opin Cardiol. 13:1998;122-129.
18. McGavin J.K., Goa K.L. Ganciclovir an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 61:2001;1153-1183.
19. Rosen H.R., Benner K.G., Flora K.D., et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation. 63:1997;476-478.
20. Corales R., Chua J., Mawhorter S., et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients an emerging clinical phenomenon? Transplant Infect Dis. 2:2000;133-139.
21. Yamani M.H., Avery R., Mawhorter S., et al. Hypogammaglobulinemia after heart transplantation impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes. Transplant Infect Dis. 3:(suppl2):2001;40-43.